Patents by Inventor Wai-Hang LEUNG
Wai-Hang LEUNG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11976116Abstract: The invention provides improved compositions for adoptive cell therapies for cancers. The invention generally provides improved vectors for generating T cell therapies and methods of using the same. More particularly, the invention provides salvage CARs, dimerizable salvage receptors, and their use in treating, preventing, or ameliorating cancers, and in particular preferred embodiments relapsed or refractory cancer. In various embodiments, a salvage chimeric antigen receptor (CAR) is provided comprising: an extracellular antigen binding domain; a multimerization domain; a transmembrane domain; one or more intracellular co-stimulatory signaling domains; and/or a primary signaling domain.Type: GrantFiled: April 14, 2017Date of Patent: May 7, 2024Assignee: 2SEVENTY BIO, INC.Inventor: Wai-Hang Leung
-
Patent number: 11952413Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: GrantFiled: December 14, 2018Date of Patent: April 9, 2024Assignee: 2SEVENTY BIO, INC.Inventor: Wai-Hang Leung
-
Publication number: 20240034768Abstract: The present disclosure provides improved compositions for adoptive T cell therapies targeting BCMA for treating, preventing, or ameliorating at least one symptom of a B cell related condition. The present disclosure also relates to adoptive T cell therapies for dual targeting of BCMA and a B cell antigen for treating, preventing, or ameliorating at least one symptom of a B cell related condition.Type: ApplicationFiled: December 13, 2019Publication date: February 1, 2024Applicant: 2seventy bio, Inc.Inventors: ALEXANDER ASTRAKHAN, WAI-HANG LEUNG
-
Publication number: 20240025963Abstract: The present disclosure provides improved compositions for adoptive T cell therapies targeting EGFR or EGRFvIII for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith. The present disclosure also relates to adoptive T cell therapies targeting EGFR or EGRFvIII and another target antigen for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: December 13, 2019Publication date: January 25, 2024Applicant: 2seventy bio, Inc.Inventors: JORDAN JARJOUR, WAI-HANG LEUNG
-
Publication number: 20230031838Abstract: The present disclosure provides adoptive T cell therapies that have improved DARIC architectures for targeting tumor antigens and recruiting TCR signaling complexes for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: September 30, 2020Publication date: February 2, 2023Applicant: 2seventy bio, Inc.Inventors: JORDAN JARJOUR, ALEXANDER ASTRAKHAN, WAI-HANG LEUNG
-
Publication number: 20220324942Abstract: The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: May 7, 2020Publication date: October 13, 2022Applicants: 2SEVENTY BIO, INC., INHIBRX, INC.Inventors: JORDAN JARJOUR, MARK POGSON, WAI-HANG LEUNG, KYLE JONES, WILLIAM CRAGO, ANGELICA SANABRIA, ANDREW HOLLANDS, JACOB GANO, MILTON MA, JOHN C. TIMMER, BRENDAN P. ECKELMAN
-
Publication number: 20220323496Abstract: The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: May 7, 2020Publication date: October 13, 2022Applicants: 2SEVENTY BIO, INC., INHIBRX, INC.Inventors: JORDAN JARJOUR, MARK POGSON, WAI-HANG LEUNG, LUCAS RASCON, ANGELICA SANABRIA, JOHN C. TIMMER, BRENDAN P. ECKELMAN
-
Publication number: 20220315638Abstract: The present disclosure provides improved CD123 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: May 7, 2020Publication date: October 6, 2022Applicants: 2SEVENTY BIO, INC., INHIBRX, INC.Inventors: JORDAN JARJOUR, MARK POGSON, WAI-HANG LEUNG, CHELSIE MACEDO, KYLE JONES, WILLIAM CRAGO, ANDREW HOLLANDS, MILTON MA, JOHN C. TIMMER, BRENDAN P. ECKELMAN
-
Publication number: 20220195039Abstract: The invention provides improved compositions for adoptive cell therapies for cancers. The invention generally provides improved vectors for generating T cell therapies and methods of using the same. More particularly, the invention provides salvage CARs, dimerizable salvage receptors, and their use in treating, preventing, or ameliorating cancers, and in particular preferred embodiments relapsed or refractory cancer. In various embodiments, a salvage chimeric antigen receptor (CAR) is provided comprising: an extracellular antigen binding domain; a multimerization domain; a transmembrane domain; one or more intracellular co-stimulatory signaling domains; and/or a primary signaling domain.Type: ApplicationFiled: April 14, 2017Publication date: June 23, 2022Applicant: 2seventy bio, Inc.Inventor: Wai-Hang LEUNG
-
Publication number: 20220031750Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: December 13, 2019Publication date: February 3, 2022Applicant: bluebird bio, Inc.Inventors: JORDAN JARJOUR, ALEXANDER ASTRAKHAN, WAI-HANG LEUNG
-
Publication number: 20220025014Abstract: The present disclosure provides improved compositions for adoptive T cell therapies targeting CD33 for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith. The present disclosure also relates to adoptive T cell therapies targeting CD33 and another target antigen for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: December 13, 2019Publication date: January 27, 2022Applicant: bluebird bio, Inc.Inventors: JORDAN JARJOUR, WAI-HANG LEUNG
-
Publication number: 20210236546Abstract: The present disclosure provides improved compositions for adoptive T cell therapies targeting NKG2D ligands for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: December 14, 2018Publication date: August 5, 2021Applicant: bluebird bio, Inc.Inventors: JORDAN JARJOUR, WAI-HANG LEUNG
-
Publication number: 20200392204Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: December 14, 2018Publication date: December 17, 2020Applicant: bluebird bio, Inc.Inventor: WAI-HANG LEUNG
-
Publication number: 20190161530Abstract: The invention provides improved compositions for adoptive immune effector cell therapies for treatment, prevention, or amelioration of numerous conditions including, but not limited to cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency.Type: ApplicationFiled: April 7, 2017Publication date: May 30, 2019Applicant: bluebird bio, Inc.Inventors: Michael T. CERTO, Wai-Hang LEUNG
-
Retinoid X receptor-gamma agonists and retinoid X receptor-alpha antagonists for treatment of cancer
Patent number: 10286000Abstract: The invention is directed to the use of Retinoid X Receptor-gamma (RXR-gamma) agonists and Retinoid X Receptor-alpha (RXR-alpha) antagonists in treatment of cancer.Type: GrantFiled: October 24, 2014Date of Patent: May 14, 2019Assignee: St. Jude Children's Research Hospital, Inc.Inventors: Wai-Hang Leung, Wing Leung -
RETINOID X RECEPTOR-GAMMA AGONISTS AND RETINOID X RECEPTOR-ALPHA ANTAGONISTS FOR TREATMENT OF CANCER
Publication number: 20160324874Abstract: The invention is directed to the use of Retinoid X Receptor-gamma (RXR-gamma) agonists and Retinoid X Receptor-alpha (RXR-alpha) antagonists in treatment of cancer.Type: ApplicationFiled: October 24, 2014Publication date: November 10, 2016Applicant: St. Jude Children's Research Hospital, Inc.Inventors: Wai-Hang LEUNG, Wing LEUNG